Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Brain tumor, adult: Astrocytoma/Astrocytic tumors
Stage/Subtype:  diffuse astrocytoma, adult
Country:  U.S.A.
Trial Type:  Treatment
Results 1-12 of 12 for your search:
Start Over
Radiation Therapy with or without Temozolomide in Treating Patients with Low-Grade Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: E3F05, NCI-2011-01971, CDR0000654697, ECOG-E3F05, NCT00978458
Poly ICLC in Treating Younger Patients With Recurrent or Progressive Low Grade Gliomas
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 0 to 21
Trial IDs: Poly-ICLC, NCI-2013-02084, NCT01188096
Carboplatin and Bevacizumab in Treating Patients with Recurrent Ependymoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CERN09-02, NCI-2011-01283, NCT01295944
Proton Beam Radiation Therapy in Treating Patients With Low Grade Gliomas and Favorable Grade 3 Gliomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-439, NCI-2011-00915, NCT01358058
Everolimus With or Without Temozolomide in Treating Patients With Newly-Diagnosed Low-Grade Gliomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 131012, NCI-2014-00749, 081184, CRAD001CUS225T, NCT02023905
Everolimus in Treating Patients With Recurrent Low-Grade Glioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 08109, NCI-2011-01701, NCT00823459
Dexanabinol in Treating Patients With Recurrent Brain Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SK01-ETS2101, NCI-2012-01204, 111827, NCT01654497
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AG120-C-002, NCI-2014-00868, NCT02073994
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Treating Patients With Brain Tumor
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 07-057, NCI-2011-02465, CDR0000628889, R21CA133859-01A1, NCT00795457
Vaccine Therapy in Treating Patients With Recurrent Gliomas After Surgery
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 08-135, NCI-2011-02491, NCT00874861
Conditioning Therapy Followed by Stem Cell Transplant in Treating Patients with High Risk or Relapsed Solid or Central Nervous System Tumors
Phase: No phase specified
Type: Treatment
Age: 70 and under
Trial IDs: 2011OC057, NCI-2013-02265, 1107M02641, MT2011-09C, NCT01505569
Vaccine Therapy and Imiquimod in Treating Patients With High Risk or Recurrent Grade II Gliomas
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 11-136, NCI-2013-00078, NCT01678352
Start Over